Aims To assess long-term outcome in a typical Western population of predominantly unfavourable patients undergoing Inoue balloon mitral valvuloplasty. Outcome amongst patients has only been undertaken in the medium term. Long-term echocardiographic data in particular are scarce.
Introduction
Balloon mitral valvuloplasty is the intervention of choice for patients with pliable mitral stenosis [1] [2] [3] [4] . Randomized comparison with surgical commissurotomy is favourable [1] [2] [3] [4] and long-term results are good [1, [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] . For patients with less optimal mitral valve morphology however, (according to the Wilkins criteria [15] ) long-term results have been less impressive, though studies are fewer [16] [17] [18] [19] [20] [21] [22] . Elderly patients in particular are underrepresented in studies -only two have specifically addressed long-term outcome in elderly patients, with relatively disappointing results [16, 22] . In Western societies the majority of patients with mitral stenosis are elderly and have unfavourable mitral valve anatomy. There are no follow-up data beyond 3 years among such patients. We therefore undertook this study to address long-term outcome in a predominantly unfavourable population.
Methods
Between June 1992 and February 1997, 118 patients underwent assessment with a view to Inoue balloon mitral valvuloplasty. Twelve patients were considered unsuitable on the basis of: left atrial thrombus (three), lack of significant transmitral gradient (four), severe coronary artery disease (two) or significant mitral regurgitation (two). One hundred and six patients therefore underwent attempted valvuloplasty. Six of these were technical failures, due to: failure to cross the mitral valve (three), failed transseptal puncture (one), tamponade following transseptal puncture (one) and subvalvar obstruction only with repeated balloon ejection (one). Long-term follow-up of the first 100 successful Inoue balloon mitral valvuloplasty cases at this institution was therefore undertaken, using clinical, echocardiographic and haemodynamic parameters.
Echocardiography
Patients underwent transthoracic and transoesophageal echocardiography in the 24 h prior to valvuloplasty. Transoesophageal images were not obtained in two patients -one had an oesophageal stricture, the other proved impossible to intubate. Mitral valve morphology was scored from transthoracic images according to the Wilkins criteria [15] . Left atrial diameter was measured in M mode from a short axis parasternal section at the level of the aortic valve [23] . Mitral valve area was calculated by planimetry or, in the absence of significant mitral regurgitation, from pressure half-time. Semiquantitative estimation of mitral regurgitation was made with colour flow mapping in parasternal long axis and apical four-chamber views.
Data collection
Data on patient age, sex, co-morbidities and prior mitral valve procedures were collected and are shown in Table 1 . Pre-procedure, patients underwent clinical assessment of NYHA class, electrocardiographic analysis of cardiac rhythm, and echocardiographic assessment of mitral valve area, mitral regurgitation and left atrial diameter. Post-procedure, patients underwent further transthoracic echocardiography, with repeat measurement of the above parameters and colour Doppler assessment of the atrial septal defect.
Balloon mitral valvuloplasty
Balloon mitral valvuloplasty was performed according to standard methodology [24] . One femoral arterial and two venous sheaths were inserted under local anaesthesia and 10 000 units of intravenous heparin was given. A pigtail catheter was advanced across the aortic valve and into the left ventricle (excluding three patients with mechanical aortic prostheses who underwent a double transseptal approach [25] ). Transseptal puncture was performed with a Brockenbrough needle and the mean transmitral diastolic gradient measured. Left ventriculography was performed to assess pre-procedural mitral regurgitation. The Inoue balloon was manoeuvred across the mitral valve to the apex of the left ventricle. The balloon was then gradually withdrawn and inflated in the mitral valve orifice to a waist diameter (26-30 mm) pre-determined according to patient height. Repeat inflations were undertaken as directed by changes in transmitral gradient and mean left atrial pressure. Haemodynamic outcome and post-procedural mitral regurgitation were assessed.
Follow-up
After discharge, patients underwent clinical review within 3 months, and subsequently at maximum intervals of 1 year. At each visit, data were collected regarding NYHA class, cardiac rhythm, left atrial diameter and mitral valve area. Local cardiologists were closely involved and records of clinical and echocardiographic examinations were obtained wherever necessary. Echocardiography was, however, not undertaken every year in all subjects, and this is reflected in the follow-up data.
Three patients were lost to follow-up, having returned to Cyprus, Ethiopia and Bosnia respectively. Five other patients moved out of region during follow-up and data were collected in collaboration with their new cardiologists.
Mean follow-up was 52 (17) months, range 24-81 months. Survival and event-free survival were assessed. Events were defined as death (all-cause), mitral valve surgery or repeat balloon mitral valvuloplasty. Restenosis following valvuloplasty (defined as loss of greater than 50% of the original increase in mitral valve area, with a valve area <1·5 cm 2 ) was also examined.
Data analysis
Baseline variables entered into univariate and multivariate analyses were demographics (age, sex), general co-morbidities (previous myocardial infarction, hypertension, diabetes, previous coronary artery bypass grafting or aortic valve surgery, malignant neoplasia, chronic renal failure or psychosis), co-morbidities related to mitral valve disease (previous cerebrovascular accident or transient ischaemic attack, systemic embolus, infective endocarditis, mitral valvuloplasty or commissurotomy), clinical condition (NYHA class and cardiac rhythm), echocardiographic variables (mitral valve morphology score, left atrial diameter, mitral valve area pre-valvuloplasty) and haemodynamic variables (mean transmitral gradient, grade of mitral regurgitation, mean left atrial pressure and mean pulmonary artery pressure). The data distribution of each variable was assessed and data are expressed as mean SD unless indicated. Survival curves were generated using the Kaplan-Meier method. Cox proportional hazards regression models were used to identify pre-procedural predictors of event-free survival and freedom from restenosis.
Results
Between June 1992 and February 1997, 106 patients underwent attempted Inoue balloon mitral valvuloplasty at this cardiothoracic centre. In 100 patients the procedure was successful. Baseline variables of these patients are shown in Table 1 . Co-morbidities were seen in the majority of patients, and one-quarter had undergone previous surgical commissurotomy. Only one in five patients was in sinus rhythm, and over half had an echocardiographic mitral valve morphology score greater than 8. Patients in sinus rhythm, with no history of commissurotomy, aged less than 65 and with a valve score W8 numbered only 12. The vast majority of patients, therefore, had at least one unfavourable characteristic for balloon mitral valvuloplasty.
Immediate results
The immediate echocardiographic and haemodynamic outcome of balloon mitral valvuloplasty is shown in Table 2 . The accepted definition of a haemodynamically successful procedure consists of an increase in mitral valve area of d50%, a post-procedural mitral valve area d1·5 cm 2 , with mitral regurgitation cgrade 2 [11, 13, 16, 17, 26] . Using these criteria, the procedure was successful in 61 patients. Initial symptomatic improvement following valvuloplasty was nonetheless seen in 88 patients.
Immediate complications
There were no in-hospital deaths. Major complications -defined as death, mitral valve surgery during the same admission, cardiac tamponade, myocardial infarction or disabling cerebrovascular accident -occurred in three of 106 procedures. These were myocardial infarction (one), cardiac tamponade (one) and embolus to the left anterior descending coronary artery (one, which was treated successfully by immediate angioplasty). Other complications included mitral regurgitation >grade 2 (five), transient inferior ST-segment elevation on the electrocardiogram (eleven) [27] , transient complete heart block (one), and vasovagal reactions requiring intravenous atropine (three).
Follow-up
Mean follow-up was 4·3 1·4 years, with a minimum of 2 completed years. Survival was 97%, 88% and 82% at 1, 3 and 6 years. Event-free survival was 96%, 82% and 56% at 1, 3 and 6 years. These data are shown in more detail in the Kaplan-Meier plots of Figs. 1 and 2.
Death intervened in 13 patients. Nine of these were cardiovascular deaths, due to: progressive heart failure (six), sudden death presumed cardiac (two) and myocardial infarction (one). Four patients died of noncardiovascular causes; these were carcinomatosis (three) and chronic renal failure (one). Mitral valve surgery was undertaken in ten patients -replacement in nine and an open valvotomy in one, of whom one subsequently died. Repeat balloon mitral valvuloplasty was performed in four patients, one of whom subsequently underwent mitral valve replacement.
Long-term assessment of NYHA class is shown in Fig. 3 . The proportion of patients occupying each category was relatively preserved over a 6-year period, but there was gradual increase in the percentage reaching a designated end-point. Mitral valve area during follow-up is shown in Fig. 4 . Left atrial diameter (5·8 1·0 cm pre-procedure) was 5·3 1·0, 5·4 1·2 and 5·6 1·4 cm at 1, 3 and 6 years respectively.
Restenosis following valvuloplasty is defined as loss of greater than 50% of the original increase in mitral valve area, with a valve area <1·5 cm [5, 6, 14, 28] . Restenosis can only be considered to have occurred in those in whom the initial procedure was successful. Using these criteria, restenosis was seen in 13 of the 61 haemodynamically successful cases (97 follow-up cases in total). Actuarial restenosis-free survival was 98%, 92% and 75% respectively at 1, 3 and 6 years.
Data analysis
Single-variable Cox regression analysis identified older age, female sex, general co-morbidities, increasing NYHA, increasing echocardiographic score, increasing left atrial size and previous history of commissurotomy as predictors of poor event-free survival. When these data were entered into a multiple Cox regression model, male sex, absence of co-morbidities, lower echocardiographic score and smaller left atrial diameter were predictors of good long-term event-free survival. The 
Long-term follow-up of mitral valvuloplasty 1693
only pre-procedural predictor of restenosis-free survival was greater pre-procedural mitral valve area.
Discussion
The patients who underwent balloon mitral valvuloplasty in this study comprised a high-risk and unfavourable population, with the highest average age, the greatest proportion of co-morbidities, the lowest incidence of sinus rhythm and the highest average echocardiographic score of any complete patient group in the world literature . Despite these adverse characteristics, the procedure was completed in 100 of 106 cases (94%), with initial symptomatic improvement in 88% of these. Procedural mortality was zero and haemodynamic success was seen in 61%. Six-year survival was 82%, but 6-year event-free survival was only 56%, illustrating the palliative nature of the procedure in this population.
Other authors have examined immediate and mid-term outcome in patient subsets with similar adverse baseline variables to ours [16] [17] [18] [20] [21] [22] . Data from these studies and the current one are shown in Table 3 . The focus of these studies was age [16, 22] , mitral valve calcification [17, 21] , echocardiographic score [18, 20] and high surgical risk [29] . As can be seen from the table, baseline demographics were broadly similar between the patient groups.
Haemodynamic success was remarkably consistent across the eight studies, at around 60% in each. In our group, 27 patients who did not have a haemodynamicallysuccessful procedure nonetheless benefited symptomatically. Sedentary elderly patients in particular may derive good symptomatic relief from small increases in mitral valve area [30] . The increase in mitral valve area was more modest than that achieved in the other studies detailed in Table 3 . However, major complications were also fewer, and it is possible that greater increase in valve area is achieved only at the expense of more frequent complications -particularly severe mitral regurgitation. It is of note that in our series, despite the adverse valve characteristics, the incidence of severe post-procedural mitral regurgitation was only 5%, lower than that reported in other suboptimal patient groups [16, 20, 22, 31] . Given the palliative nature of the procedure, it is perhaps better to accept a moderate result at low procedural risk than to strive for a more impressive result at increased risk of major complications.
Follow-up was for a longer time than reported in any other study of mitral valvuloplasty in patients with adverse characteristics. Additionally, there were good echocardiographic data available on follow-up. Survival and event-free survival were both greater than in comparable studies. This reflects both the low immediate complication rate, and perhaps a relative reluctance to intervene further in some patients. This possibility is suggested by the significant proportion of event-free survivors (about 15%) who were in NYHA class III during follow-up.
Diminution in mitral valve area post-valvuloplasty was gradual, and the actuarial restenosis rate at 6 years was only 25%. Even when increase in mitral valve area is only moderate, it is many years before the mitral valve orifice diminishes to pre-valvuloplasty levels.
Pre-procedural predictors of long-term event-free survival were male sex, absence of co-morbidities, lower echocardiographic score and smaller left atrial diameter. Male sex [18] , lower echocardiographic score [8, 11, 13, 32, 33] and smaller left atrial diameter [13] have been previously identified. Other cited pre-procedural predictors of event-free survival have included age [12, 20, 21, 32] , NYHA class [11, 16, 20, 32] sinus rhythm [20, 21] , previous commissurotomy [13, 19, 20] , mitral valve calcification [17, 34] , tricuspid regurgitation [35] and mitral valve area [33] .
Limitations
This study includes a small number of patients -12 -in whom there were no specific adverse characteristics. Whilst this may be considered to have skewed the data favourably, our intention was to present a complete dataset from a typical Western population, in order to establish the overall long-term results that might be expected in such a patient group. As such, all patients presenting for valvuloplasty were included. Event-free survival included some patients who, for various reasons, remained in NYHA class 3. Some studies exclude such patients, and this would have influenced analysis. However, we felt that to include NYHA class 3 as an 'event' would be more misleading than to exclude it in a population with such a high prevalence of co-morbidities.
Echocardiographic follow-up data are not complete, and this is reflected in Fig. 4 . All patients in whom measurements of valve area were available are included in Fig. 4 , which therefore is a reflection of Table 3 Comparison with other studies of patient subsets with adverse characteristics Zhang et al. [21] Iung et al. [22] Post et al. [18] Tuzcu et al. [17] Lefevre et al. [28] Palacio et al. [20] Tuzco et al. [16] Current study 
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changes in valve area after valvuloplasty, rather than specifically of restenosis, which was itself analysed separately.
Conclusions
In patients with pliable mitral stenosis, balloon mitral valvuloplasty is the procedure of choice. Likewise, in very elderly, frail or otherwise surgically inoperable patients, valvuloplasty may provide adequate relief from symptoms for a period of time at low procedural risk and is therefore the procedure of choice. In patients with calcified, thickened valves who are fit for surgery, the decision is more difficult. Inoue mitral valvuloplasty offers the prospect of reasonable symptom relief on a minimally invasive basis, whereas mitral valve replacement promises more substantial relief from symptoms, but at significant morbidity and mortality. Inoue mitral valvuloplasty in patients with unfavourable characteristics is a palliative procedure; therefore the aim should be to achieve moderate increase in mitral valve area at low risk, rather than strive for substantial increase in valve area at significant risk.
